1. Home
  2. CGEM vs NVTS Comparison

CGEM vs NVTS Comparison

Compare CGEM & NVTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEM
  • NVTS
  • Stock Information
  • Founded
  • CGEM 2016
  • NVTS 2014
  • Country
  • CGEM United States
  • NVTS United States
  • Employees
  • CGEM N/A
  • NVTS N/A
  • Industry
  • CGEM Biotechnology: Pharmaceutical Preparations
  • NVTS Semiconductors
  • Sector
  • CGEM Health Care
  • NVTS Technology
  • Exchange
  • CGEM Nasdaq
  • NVTS Nasdaq
  • Market Cap
  • CGEM 730.2M
  • NVTS 762.1M
  • IPO Year
  • CGEM 2021
  • NVTS N/A
  • Fundamental
  • Price
  • CGEM $10.55
  • NVTS $3.45
  • Analyst Decision
  • CGEM Strong Buy
  • NVTS Strong Buy
  • Analyst Count
  • CGEM 7
  • NVTS 7
  • Target Price
  • CGEM $31.67
  • NVTS $4.75
  • AVG Volume (30 Days)
  • CGEM 551.6K
  • NVTS 5.1M
  • Earning Date
  • CGEM 03-13-2025
  • NVTS 02-27-2025
  • Dividend Yield
  • CGEM N/A
  • NVTS N/A
  • EPS Growth
  • CGEM N/A
  • NVTS N/A
  • EPS
  • CGEM N/A
  • NVTS N/A
  • Revenue
  • CGEM N/A
  • NVTS $91,381,000.00
  • Revenue This Year
  • CGEM N/A
  • NVTS $8.34
  • Revenue Next Year
  • CGEM N/A
  • NVTS $5.50
  • P/E Ratio
  • CGEM N/A
  • NVTS N/A
  • Revenue Growth
  • CGEM N/A
  • NVTS 38.99
  • 52 Week Low
  • CGEM $9.50
  • NVTS $1.75
  • 52 Week High
  • CGEM $30.19
  • NVTS $7.40
  • Technical
  • Relative Strength Index (RSI)
  • CGEM 38.45
  • NVTS 50.59
  • Support Level
  • CGEM $10.14
  • NVTS $3.21
  • Resistance Level
  • CGEM $11.31
  • NVTS $3.62
  • Average True Range (ATR)
  • CGEM 0.64
  • NVTS 0.36
  • MACD
  • CGEM 0.01
  • NVTS -0.04
  • Stochastic Oscillator
  • CGEM 30.11
  • NVTS 32.52

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components for use in mobile device and other markets. Geographically, the company operates in China, Europe, United States, Rest of Asia and Others. The majority of revenue is generated from China.

Share on Social Networks: